RASSF10 and neoplasm: We could also show that in independent data sets RASSF10 loss correlated not only with reduced patient survival rates, but also with tumor stage/grade and was found in different kidney entities (clear cell carcinoma, papillary cell carcinoma, and chromophobe cell cancer).